Grace Therapeutics (GRCE) Assets Average (2018 - 2026)
Grace Therapeutics (GRCE) posted Assets Average of $67.6 million for Q1 2026, little changed sequentially from $67.5 million in Q4 2025, and up 1.45% YoY from $66.6 million in Q1 2025.
Grace Therapeutics (GRCE) Assets Average (2018 - 2026) Analysis & Trends
Grace Therapeutics has reported Assets Average for 9 years, with the latest figure at $67.6 million in Q1 2026.
- Quarterly Assets Average rose 1.45% year-over-year to $67.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $67.6 million (up 1.45% YoY) and the FY2026 annual result came in at $69.3 million, down 4.57% from the prior year.
- Assets Average was little changed at $67.6 million in Q1 2026 per GRCE's latest filing, from $67.5 million in the prior quarter.
- Over five years, Assets Average peaked at $126.8 million in Q2 2022 and troughed at $63.3 million in Q4 2024.
- A 5-year average of $84.4 million and a median of $74.7 million in 2024 frame the typical range for Assets Average.
- The sharpest annual moves came in 2022 and 2023: Assets Average jumped 161.8% in 2022, then plunged 39.99% in 2023.
- Over 5 years, Assets Average stood at $118.9 million in 2022, then slumped by 35.05% to $77.2 million in 2023, then retreated by 18.02% to $63.3 million in 2024, then increased by 6.71% to $67.5 million in 2025, then increased by 0.06% to $67.6 million in 2026.
- According to Business Quant data, Assets Average over the past three periods registered $67.6 million, $67.5 million, and $68.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 11.22 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 8.86 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 5.34 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 25.27 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 2.09 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 19.82 Bn |
| 10 | Grace Therapeutics | 37.99 Mn | 37.99 Mn | - | 58.36 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 58.36 Mn |
| Mar 31, 2026 | 67.57 Mn |
| Dec 31, 2025 | 67.53 Mn |
| Sep 30, 2025 | 68.19 Mn |
| Jun 30, 2025 | 70.90 Mn |
| Mar 31, 2025 | 66.61 Mn |
| Dec 31, 2024 | 63.29 Mn |
| Sep 30, 2024 | 67.53 Mn |
| Jun 30, 2024 | 71.51 Mn |
| Mar 31, 2024 | 74.74 Mn |
| Dec 31, 2023 | 77.20 Mn |
| Sep 30, 2023 | 75.62 Mn |
| Jun 30, 2023 | 76.08 Mn |
| Mar 31, 2023 | 97.96 Mn |
| Dec 31, 2022 | 118.86 Mn |
| Sep 30, 2022 | 122.92 Mn |
| Jun 30, 2022 | 126.78 Mn |
| Mar 31, 2022 | 121.42 Mn |
| Dec 31, 2021 | 117.01 Mn |
| Sep 30, 2021 | 90.12 Mn |